The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma

Edward J. Fox, Jesse T. Torbert, Anne Marie Martin, Arthur P. Staddon, Joseph L. Finstein, Richard D. Lackman

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Currently, the only treatment available for recurrent/metastatic chondrosarcoma is further surgical resection. Fluoroquinolones have shown toxicity in immature cartilage, inducing apoptosis and inhibiting the proliferation of human chondrosarcoma cells. Since previous studies suggested that ciprofloxacin and paclitaxel act synergistically in slowing the growth of chondrosarcoma in vitro, we investigated their effects on human recurrent/metastatic chondrosarcoma. Four patients received oral ciprofloxacin (750 mg twice daily) and intravenous paclitaxel (90 mg/m2) for 6-8 weeks of each cycle. Patient 1 remained stable 32.8 weeks after initiation of treatment. Patient 2 showed a 60% decrease in tumor growth but progressed by 10.3 weeks. Patient 3 progressed over 9 weeks, remained stable for 16 months, and then progressed after treatment with paclitaxel was discontinued. Patient 4 had three lesions: the recurrent lesion progressed despite treatment, showing an 8% increase in growth; one metastatic lesion remained stable (18 weeks), and the second metastatic lesion progressed. Gene expression profiling of normal articular cartilage and human chondrosarcoma cells exposed to ciprofloxacin showed differential expression of the genes DDX5, MYST2, ISGF3, APC, RPL3, EIF4C2, and ERH, all of which are involved in cell proliferation, cell-cycle regulation, or apoptosis.

Original languageEnglish (US)
Pages (from-to)516-522
Number of pages7
JournalCommunity Oncology
Issue number6
StatePublished - Jan 1 2005

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology


Dive into the research topics of 'The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma'. Together they form a unique fingerprint.

Cite this